




About Genmab

Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged transactional research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030 Genmab's vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines.

How we Operate



At-a-glance

Genmab's Growing Organization & Growing Presence

Princeton, USA

- Translational Research
- Development
- U.S Market Operations
- Corporate Functions

Utrecht, NL

- Research
- Translational Research
- Antibody Product Creation
- Corporate Functions

Copenhagen, DK

- HQ
- CMC Operations
- Clinical Operations
- Corporate Functions

Tokyo, JP

- Japan Clinical
- Japan Market Operations
- Corporate Functions

Our Strengths & Differentiators

- **World-Class** antibody biology knowledge and deep insight into disease targets
- **Discovery and development engine** with proprietary technologies that allow us to build a world-class pipeline
- **In-house expertise** with solid track record of building successful strategic partnerships
- **Robust pipeline** of potential best-in-class and first-in-class therapies
- **Experienced, diverse** leadership team

Operational

7

Approved Medicines Including Genmab's Innovation

Tivdak[®], first Genmab owned product on market. Genmab owned, co-developed and co-promoted in partnership with Seagen EPKINLY[™] in partnership with AbbVie, second Genmab owned product on market DARZALEX[®], RYBREVANT[®] and TECVAYLI[®] discovered and/or developed & marketed by Janssen Kesimpta[®] developed & marketed by Novartis TEPEZZA[®] developed & marketed by Horizon Therapeutics

4

Proprietary* Technologies

DuoBody[®] platform, HexaBody[®] platform, DuoHexaBody[®] platform & HexElect[®] platform

9

Proprietary* Antibody Products in Clinical Development


Tisotumab vedotin, epcoritamab, DuoBody-PD-L1x4-1BB (GEN1046/BNT311), DuoBody-CD40x4-1BB (GEN1042/BNT312), HexaBody-CD27 (GEN1053/BNT313), GEN1056 (BNT322), DuoHexaBody-CD37 (GEN3009), HexaBody-CD38 (GEN3014), DuoBody-CD3xB7H4 (GEN1047)

42

Cumulative INDs since 1999

Created by Genmab or with Genmab's technologies

2022 Financials (DKK)



Our Purpose

Our unstoppable team will improve the lives of patients through innovative and differentiated antibody therapeutics

Our Vision

By 2030, our KYSO antibody medicines are fundamentally transforming the lives of people with cancer and other serious diseases

Our Values

- Passion for Innovation
- Determined - being the best at what we do
- Integrity - we do the right thing
- We work as one team & respect each other

Our Strategy

- Focus on core competence
- Turn science into medicine
- Build a profitable and successful biotech

Strong Pipeline of Potential 1st-in-class/Best-in-class Product Candidates Innovative Pipeline: Genmab's Proprietary¹ Products

Product	Developed By	Disease Indications	Most Advanced Development Phase				
			Pre-clinical	1	1/2	2	3
Tisotumab vedotin	Co-development Genmab / Seagen	Cervical cancer					
		Solid tumors					
Epcoritamab	Co-development Genmab / AbbVie	Relapsed/refractory DLBCL					
		Relapsed/refractory FL					
		First Line DLBCL					
		B-cell NHL					
		Relapsed/refractory CLL & Richter's Syndrome					
		Indolent NHL pediatric patients					
(DuoBody-PD-L1x4-1BB (GEN1046/BNT311))	Co-development Genmab / BioNTech	NSCLC					
		Solid tumors					
DuoBody-CD40x4-1BB (GEN1042/BNT312)	Co-development Genmab / BioNTech	Solid tumors					
HexaBody-CD38 (GEN3014)	Genmab ²	Hematologic malignancies					
DuoHexaBody [®] -CD37 (GEN3009)	Genmab	Hematologic malignancies					
DuoBody-CD3xB7H4 (GEN1047)	Genmab	Solid tumors					
HexaBody-CD27 (GEN1053/BNT313)	Co-development Genmab / BioNTech	Solid tumors					
GEN1056 (BNT322)	Co-development Genmab / BioNTech	Solid tumors					

Programs Incorporating Genmab's Innovation and Technology ≥Phase 2 Development³

Product	Target	Developed By	Disease Indications	Most Advanced Development Phase				
				Pre-clinical	1	1/2	2	3
Daratumumab	UltiMab [®]	Janssen	MM AL Amyloidosis					
Teprotumumab	UltiMab	Horizon	Thyroid eye disease					
Amivantamab	DuoBody	Janssen	NSCLC Adv. or metastatic gastric or esophageal cancer Adv. or metastatic colorectal cancer					
Teclistamab	DuoBody	Janssen	MM					
Talquetamab	DuoBody	Janssen	RRMM					
Inclacumab	UltiMab	Pfizer (Global Blood Therapeutics)	Vaso-occlusive crises in sickle cell disease					
Mim8	DuoBody	Novo Nordisk	Hemophilia A					
Ordesekimab	UltiMab	Provention Bio	Celiac disease					
Lu AF82422	UltiMab	Lundbeck	Multiple system atrophy					

Proprietary Technologies Allow us to Build a World-class Pipeline

DuoBody Platform

- Bispecific antibody technology platform
- Potential in cancer, autoimmune, infectious, cardiovascular, central nervous system diseases and hemophilia
- Multiple commercial & research collaborations

HexaBody Platform

- Enhanced potency antibody technology platform
- Broadly applicable technology that builds on natural antibody biology

DuoHexaBody Platform

- Antibody technology that combines **DuoBody** and **HexaBody** platforms
- Creates bispecific antibodies with target mediated enhanced potency

HexElect Platform

- Antibody technology platform inspired by **HexaBody** platform
- Combines dual targeting with enhanced selectivity & potency

Executive Management

- Jan G. J. van de Winkel, Ph.D., President & CEO
- Anthony Pagano, EVP & CFO
- Judith Klimovsky, M.D., EVP & CDO
- Anthony Mancini, EVP & COO
- Tahamtan Ahmadi, M.D., Ph.D., EVP & CMO
- Birgitte Stephensen, EVP & CLO
- Christopher Cozic, EVP & CPO
- Martine J. van Vugt, Ph.D., EVP & CSO

Notes

*Tisotumab vedotin 50:50 partnership with Seagen; epcoritamab 50:50 partnership with AbbVie; DuoBody-PD-L1x4-1BB, DuoBody-CD40x4-1BB, HexaBody-CD27 and GEN1056 50:50 partnership with BioNTech; HexaBody-CD38, exclusive worldwide license and option agreement with Janssen Biotech, Inc.

1Certain product candidates in development with partners, as noted

2Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc.

3Products discovered and/or developed and marketed by others incorporating Genmab technology and innovation.

This document contains forward looking statements that involve significant risks and uncertainties. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's most recent Annual Report on form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. August 3, 2023